Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
9.94%
EBIT to Interest (avg)
-33.02
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.61
Sales to Capital Employed (avg)
0
Tax Ratio
6.22%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.13
EV to EBIT
-0.51
EV to EBITDA
-0.53
EV to Capital Employed
0.46
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-90.49%
ROE (Latest)
-131.73%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Movement
Not enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for PHAXIAM Therapeutics SA
Net Profit
Higher at EUR -9.07 MM
than preceding 12 month period ended Jun 2024MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (EUR MM)
Operating Cash Flow
Highest at EUR -43.81 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (EUR MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for PHAXIAM Therapeutics SA
Debt-Equity Ratio
Highest at 74.22 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Cash and Eqv
Lowest at EUR 1.46 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents






